TD Cowen lowered the firm’s price target on TransMedics (TMDX) to $120 from $175 and keeps a Buy rating on the shares. The firm said TransMedics is moving beyond the early innings of the Organ Care System (OCS) and National OCS Program (NOP) launches so the company s quarterly revenue performances have become levered to the US transplant market trends. Therefore it is becoming more important for investors to track and understand transplant volume growth.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TMDX:
- TransMedics Group call volume above normal and directionally bullish
- McDonald’s, Ford, Pfizer report Q3 earnings beats: Morning Buzz
- TransMedics price target lowered to $109 from $208 at Needham
- TransMedics price target lowered to $125 from $200 at Oppenheimer
- TransMedics price target lowered to $109 from $169 at Canaccord